Eli Lilly and Co (XSWX:LLY) 3-1 Month Momentum %: 26.57% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:LLY Eli Lilly and Co XSWX:LLY
97 GF Score
Price CHF925.00
GF Value CHF1,133.65
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co 3-1 Month Momentum %?

Eli Lilly and Co XSWX:LLY -1.60% 97 3-1 Month Momentum % is 26.57% as of Jul. 16, 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 97/100 and a GF Value™ of CHF1,133.65 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,026 Drug Manufacturers companies, Eli Lilly and Co ranks better than 91.23% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-16), Eli Lilly and Co's 3-1 Month Momentum % is 26.57%.

The industry rank for Eli Lilly and Co's 3-1 Month Momentum % or its related term are showing as below:

XSWX:LLY's 3-1 Month Momentum % is ranked better than
91.23% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -8.36 vs XSWX:LLY: 26.57

Eli Lilly and Co  (XSWX:LLY) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Eli Lilly and Co 3-1 Month Momentum % Related Terms

XSWX:LLY vs JNJ, ABBV, MRK: 3-1 Month Momentum % Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eli Lilly and Co 3-1 Month Momentum % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's 3-1 Month Momentum % falls into.


XSWX:LLY
97GF Score
Eli Lilly and Co XSWX:LLY
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co  (XSWX:LLY) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 26.57% mean?
Eli Lilly and Co (XSWX:LLY) has a 3-1 Month Momentum % of 26.57% as of Jul. 16, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Eli Lilly and Co and its competitors. According to the industry distribution chart, Eli Lilly and Co ranks #90 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is Eli Lilly and Co's 3-1 Month Momentum % too high?
Eli Lilly and Co's current 3-1 Month Momentum % is 26.57%. Based on the distribution chart, Eli Lilly and Co ranks #90 out of 1026 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's 3-1 Month Momentum % compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #90 out of 1026 companies for 3-1 Month Momentum %. This places Eli Lilly and Co in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current 3-1 Month Momentum % is 26.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,133.65, compared to a current price of CHF925.00 — trading 18.4% below its estimated fair value. The current 3-1 Month Momentum % is 26.57%. Eli Lilly and Co's overall GF Score™ is 97/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current 3-1 Month Momentum % is 26.57% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF925.00 is trading 18.4% below its estimated GF Value™ of CHF1,133.65. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • 3-1 Month Momentum %: 26.57%
  • GF Value™: CHF1,133.65 vs. price of CHF925.00 (18.4% below fair value)
  • GF Score™: 97/100 with 4 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
97GF Score

Get the complete analysis for XSWX:LLY

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF925.00
Price
CHF1,133.65
GF Value